Skip to main content

Gastric Adenocarcinoma clinical trials at UCSF
3 in progress, 0 open to new patients

  • A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)

    Sorry, in progress, not accepting new patients

    This is a study of pembrolizumab (MK-3475) for advanced gastric or gastroesophageal junction adenocarcinoma; pembrolizumab will be given as monotherapy to participants who have had previous treatment or who are treatment-naïve; pembrolizumab will also be evaluated as combination therapy with cisplatin and 5-Fluorouracil (5-FU) or (Japan only) capecitabine in treatment-naïve participants. The primary study hypothesis is that pembrolizumab will provide a clinically meaningful Overall Response Rate (ORR).

  • Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

    Sorry, in progress, not accepting new patients

    The primary objective of this study is to evaluate and compare the efficacy of andecaliximab (GS-5745) in combination with nivolumab versus nivolumab alone in adults with recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma.

    San Francisco, California and other locations

  • Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)

    Sorry, in progress, not accepting new patients

    This is a study of pembrolizumab (MK-3475) as first-line treatment for participants with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. Participants will be randomly assigned to one of the three treatment arms of the study: pembrolizumab as monotherapy, or pembrolizumab + cisplatin + 5-fluorouracil (5-FU) or capecitabine, or placebo + cisplatin + 5-FU or capecitabine. The primary study hypotheses are that pembrolizumab in combination with chemotherapy is superior to chemotherapy alone in terms of Progression-free Survival (PFS) and Overall Survival (OS) in participants with programmed death-ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 and that pembrolizumab combination with chemotherapy is superior to chemotherapy alone in terms of OS in participants with PD-L1 CPS ≥10. Primary study hypotheses also are that pembrolizumab monotherapy non-inferior to chemotherapy alone in terms of OS in participants PD-L1 CPS ≥1 and is superior to chemotherapy alone in terms of OS in participants with PD-L1 CPS ≥1 and in participants with PD-L1 CPS ≥10.